The Efficacy of Amway Uric Acid Lowering Product on Hyperuricemia

Status Recruiting

Clinical Trial Summary

The goal of this three arms, randomized, double-blind controlled interventional study is to evaluate the efficacy of Amway uric acid lowering product improving hyperuricemia in patients aged 18 and 65 years old. The main question it aims to answer is: - whether the serum uric acid level of patients with hyperuricemia could be significantly lowered after 3 months intervention with Amway uric acid lowering product 180 eligible participants will be enrolled in one study site and randomized to three study groups (two product group and one placebo group), who will consume the assigned products for 3 months and be arranged to 3 site visits. All relevant clinical data will be captured and recorded into CTMS (Clinical Trial Management System) for statistical analysis and reporting. Researchers will compare the three study groups to conclude how Amway uric acid lowering product will improve hyperuricemia.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Hyperuricemia

Clinical Trial Details

NCT number	NCT06084585
Study type	Interventional
Source	Amway (China) R&D Center
Contact	Charlie Zhang, MD
Phone	+8613901981272
Email	charlie.zhang@raisonbiotech.com
Status	Recruiting
Phase	N/A
Start date	October 23, 2023
Completion date	March 15, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05434858` - Imagery as Biomarker of Gout	N/A
Completed	`NCT04060173` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671	Phase 1
Recruiting	`NCT05504083` - Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients	Phase 2
Completed	`NCT04966325` - Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects	Early Phase 1
Completed	`NCT01407874` - A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency	Phase 2
Completed	`NCT00995618` - Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia	Phase 2
Completed	`NCT00288158` - Primary Prevention of Hypertension in Obese Adolescents	Phase 2
Terminated	`NCT04987294` - Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease	Phase 2
Completed	`NCT04236219` - ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers	Phase 1
Completed	`NCT06189404` - Effect of Tigulixostat on the Pharmacokinetics of Theophylline	Phase 1
Recruiting	`NCT05586958` - Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients	Phase 3
Recruiting	`NCT06056570` - Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia	Phase 1/Phase 2
Not yet recruiting	`NCT04586803` - Study on the Bioavailability of Three Different Prescription Processes of SHR4640 Tablets in Healthy Volunteers	Phase 1
Completed	`NCT02959918` - Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid	Phase 2
Not yet recruiting	`NCT02944214` - Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients	N/A
Completed	`NCT02557126` - Study of URC102 to Assess the Safety and Efficacy in Gout Patients	Phase 2
Active, not recruiting	`NCT01021241` - Safety and Efficacy Study of Intravenous Uricase-PEG 20	Phase 1
Completed	`NCT00756964` - Lowering Serum Uric Acid to Prevent Acute Kidney Injury	Phase 2
Terminated	`NCT00607152` - Rasburicase (Fasturtec) Registration Trial	Phase 3
Completed	`NCT03906006` - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects	Phase 1